Scarica l'app Stockscreener
0.6331
6.18%
-0.0417
Dopo l'orario di chiusura:
.68
0.0469
+7.41%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.6748
Aprire:
$0.65
Volume 24 ore:
54,519
Relative Volume:
0.07
Capitalizzazione di mercato:
$4.09M
Reddito:
-
Utile/perdita netta:
$-6.07M
Rapporto P/E:
-0.1095
EPS:
-5.78
Flusso di cassa netto:
$-7.34M
1 W Prestazione:
-5.12%
1M Prestazione:
-15.60%
6M Prestazione:
-34.81%
1 anno Prestazione:
-48.11%
Intervallo 1D:
$0.62
$0.6999
Intervallo di 1 settimana:
$0.62
$0.72
Portata 52W:
$0.614
$3.10
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Nome
Adial Pharmaceuticals Inc
Settore
Industria
Telefono
434-422-9800
Indirizzo
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Confronta ADIL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.6331 | 4.09M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2018-10-30 | Iniziato | Maxim Group | Buy |
| 2018-10-11 | Iniziato | Dawson James | Buy |
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D. - ACCESS Newswire
Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder - ACCESS Newswire
Alcohol Use Disorder Treatment Market: Discover the Best - openPR.com
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 19.8% in March - Defense World
Adial Pharmaceuticals Appoints Tony Goodman as COO - TipRanks
Adial Pharmaceuticals appoints new COO Tony Goodman - Investing.com
Litchfield Hills Research Predicts ADIL Q1 Earnings - Defense World
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Grows By 610.2% - Defense World
Adial Pharma stock hits 52-week low at $0.69 amid market challenges - Investing.com
Brookline Capital Management Estimates ADIL Q1 Earnings - Defense World
Rodman & Renshaw maintains Adial stock Buy rating, $8 target By Investing.com - Investing.com Australia
Rodman & Renshaw maintains Adial stock Buy rating, $8 target - Investing.com India
Adial Pharma stock hits 52-week low at $0.71 amid market challenges - Investing.com
Adial Pharma stock hits 52-week low at $0.71 amid market challenges By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update - GlobeNewswire
ADIAL PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Adial Pharmaceuticals expects cash to fund operations into 2H of 2025 - TipRanks
Can Adial's FDA-Approved Strategy for Alcohol Treatment Offset Its Widening Losses? - StockTitan
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial - ACCESS Newswire
Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA - ACCESS Newswire
Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits - ACCESS Newswire
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia - accessnewswire.com
Adial Pharmaceuticals Receives Positive FDA Feedback on In Vitro Bridging Strategy for AD04 - Defense World
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland - ACCESS Newswire
Adial gets FDA nod for Phase 3 drug strategy By Investing.com - Investing.com Australia
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs - AOL.com
Adial gets FDA nod for Phase 3 drug strategy - Investing.com India
Adial Pharmaceuticals Receives Positive Response from FDA - GlobeNewswire
Adial Pharmaceuticals Receives FDA's Positive Feedback On AD04 In Vitro Bridging Strategy - Nasdaq
Adial Pharmaceuticals Advances AD04 with FDA Approval - TipRanks
Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - StockTitan
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder - Benzinga
Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City - ACCESS Newswire
Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare - ACCESS Newswire
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia - ACCESS Newswire
Adial Pharmaceuticals secures patent for genetic addiction treatment By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Granted New U.S. Patent Expanding - GlobeNewswire
Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders - Marketscreener.com
Adial Granted New U.S. Patent Expanding Genetic-Based Approach For Addiction Treatment - Nasdaq
Adial Pharmaceuticals secures patent for genetic addiction treatment - Investing.com
This Groundbreaking Patent Could Transform How We Treat AddictionHere's Why Genetics Matter - StockTitan
Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria - ACCESS Newswire
Adial Is Filling The Gap In Alcohol Use Disorder Treatment With Repurposed Drug - Citeline News & Insights
Adial Pharmaceuticals secures new patent for addiction treatment By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Significant Growth in Short Interest - Defense World
Adial Pharmaceuticals secures new patent for addiction treatment - Investing.com India
Adial Pharmaceuticals Awarded U.S. Patent For Genotype-Specific Treatment Of Opioid Disorders - Nasdaq
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - The Manila Times
Adial Pharmaceuticals Secures Patent for Genetically Targeted Treatment Methods in Addiction Therapy - Nasdaq
Revolutionary Patent Win: Adial's DNA-Guided Solution Takes On $35B Addiction Crisis - StockTitan
Adial Pharmaceuticals Inc Azioni (ADIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):